Mazdutide
GLP-1 / Glucagon dual agonist
A dual GLP-1/glucagon agonist in clinical development.
Half-life
~ several days (once-weekly)
Mol. weight
~ 4 kDa (modified dual agonist)
Sequence
GLP-1 / glucagon-based dual agonist
Discussions
0 threads
Overview
Mazdutide is an investigational once-weekly dual agonist of the GLP-1 and glucagon receptors, in clinical development (notably in China) for obesity and type 2 diabetes. By combining GLP-1's appetite suppression with glucagon's potential to increase energy expenditure, it targets the same dual-receptor rationale as survodutide.
Mechanism of action
Mazdutide activates both GLP-1 and glucagon (GCG) receptors. GLP-1 agonism drives glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and satiety; glucagon agonism may additionally increase energy expenditure and reduce hepatic fat. The combination is intended to produce weight loss through both reduced intake and increased expenditure.
Researched benefits
- Dual GLP-1 + glucagon agonism
- Studied for weight loss and glycemic control
- Glucagon component may increase energy expenditure
- Once-weekly dosing (investigational)
Considerations
- Investigational; not approved in most jurisdictions
- Glucagon agonism adds a novel safety profile under study
- GI side effects expected
- Requires medical supervision
Key Academic Literature & Studies
Search more in PubMedPeer-reviewed citations and clinical trials evaluating Mazdutide in scientific literature.
Query PubMed for recent peer-reviewed preclinical and clinical publications on Mazdutide:
View Mazdutide index on PubMed (NCBI)